A Phase 1 interventional study of Lemzoparlimab and Dexamethasone in Multiple Myeloma, sponsored by AbbVie. Terminated at 32 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-06.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Multiple Myeloma by AbbVie — 7 open to participants now, 17 under way, 5 of them phase 3. Multiple Myeloma · AbbVie.
Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 32nd largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2022, is one of 18 in phase 1, and was the 28th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →7 of the 40 studies in Multiple Myeloma by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Israel, Japan and 1 more country
Ages 18+
AbbVie · Sites in United States, China, Israel and 1 more country
Ages 18+
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
AbbVie · Sites in United States, Australia, Canada and 4 more countries
Ages 18+
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
By country, each count listing its studies:
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 16 · Phase 3 6
First in 2005; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 84 across the 39 interventional studies, 514 across the 1 observational. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
3 of the studies in Multiple Myeloma by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT06223516AbbVieStudy of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | 2027-02 |
| NCT02899052AbbVieStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Multiple Myeloma by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multiple myeloma (MM) accounts for more than 10% of all blood cancers and 1% of all cancers. The purpose of this study is to assess how safe lemzoparlimab is and how lemzoparlimab moves through the body of adult participants with MM when given with or without dexamethasone, and in combination with other anti-myeloma regimens. Adverse events and change in disease activity will be assessed.
Lemzoparlimab is an investigational drug being developed for the treatment of relapsed/refractory (R/R) MM. Study doctors put the participants in groups called treatment arms. Two different dose levels of lemzoparlimab will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of lemzoparlimab, followed by a dose expansion phase to confirm the dose. Approximately 163 adult participants with R/R MM will be enrolled in the study in approximately 60 sites worldwide.
In the Dose Escalation arms, participants will receive intravenous (IV) lemzoparlimab with or without dexamethasone (oral/IV) in combination with pomalidomide (oral) or carfilzomib (IV) or subcutaneous (SC) daratumumab in 28-day cycles. In the Dose Expansion arms, participants will receive lemzoparlimab (IV) alone or with dexamethasone (oral/IV) in combination with pomalidomide (oral) or carfilzomib (IV) or daratumumab (SC) in 28-day cycles.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests and side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma Working Group (IMWG) criteria.
Arm A - Lemzoparlimab with or without Dexamethasone
Arm B - Lemzoparlimab + Pomalidomide-Dexamethasone
Arm C - Lemzoparlimab + Carfilzomib-Dexamethasone
Exclusion Criteria:
Arm B - Lemzoparlimab + Pomalidomide-Dexamethasone
Arm C - Lemzoparlimab + Carfilzomib-Dexamethasone
Arm D - Lemzoparlimab + Daratumumab-Dexamethasone
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive lemzoparlimab in 28 day cycles.
Biological: Lemzoparlimab
Participants will receive lemzoparlimab + pomalidomide + dexamethasone in 28 day cycles.
Biological: Lemzoparlimab · Drug: Dexamethasone · Drug: Pomalidomide
Participants will receive lemzoparlimab + carfilzomib + dexamethasone in 28 day cycles.
Biological: Lemzoparlimab · Drug: Dexamethasone · Drug: Carfilzomib
Participants will receive lemzoparlimab + daratumumab + dexamethasone in 28 day cycles.
Biological: Lemzoparlimab · Drug: Dexamethasone · Biological: Daratumumab
Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion in 28 day cycles.
Biological: Lemzoparlimab
Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + dexamethasone in 28 day cycles.
Biological: Lemzoparlimab · Drug: Dexamethasone
Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + pomalidomide + dexamethasone in 28 day cycles.
Biological: Lemzoparlimab · Drug: Dexamethasone · Drug: Pomalidomide
Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + carfilzomib + dexamethasone in 28 day cycles.
Biological: Lemzoparlimab · Drug: Dexamethasone · Drug: Carfilzomib
Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + daratamumab + dexamethasone in 28 day cycles.
Biological: Lemzoparlimab · Drug: Dexamethasone · Biological: Daratumumab
Intravenous (IV) infusion
Also known as: TJ011133
Oral tablet or IV infusion/injection
IV infusion
Oral capsule
Subcutaneous (SC) injection
Dose Limiting Toxicities (DLTs) of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-myeloma Regimens in Participants With Relapsed/Refractory (R/R) Multiple Myeloma (MM)
DLT events as described in the protocol will be assessed.
Time frame: Up to 28 days after study drug administration
Percentage of Participants Achieving Best Overall Response of Documented Partial Response (PR) or Better
Best overall response is defined as achieving documented PR or better at two consecutive disease assessments during the study, according to International Myeloma Working Group (IMWG) 2016 criteria.
Time frame: Up to approximately 2 years
Progression Free Survival (PFS)
PFS is defined as the time from the first dose of study drug to the first documented progressive disease (PD) or death due to any cause, whichever occurs first.
Time frame: Up to approximately 2 years
Duration of Response (DOR)
DOR is defined as the time from first documented response (PR or better) to the first documented PD or death due to MM, whichever occurs first.
Time frame: Up to approximately 2 years
Time to Progression (TTP)
TTP is defined as the time from the first dose of study drug to the first documented PD or death due to MM, whichever occurs first.
Time frame: Up to approximately 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Jun 2022, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lemzoparlimab